WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Regulating Medicines in Europe – An In-Depth Analysis of the European Medicines Regulatory Network and Its Evolving Framework

[1]Mr. Mubeen Ahmad Mohammad Aarif, [2]Mr. Nitin Parshuram Rathod.

[1.] Prof. Aditya Institute Of Pharmacy, Chalisgaon, Dhule road, Tal. Chalisgaon, Dist. Jalgaon.
[2.] Student. Aditya Institute Of Pharmacy, Chalisgaon, Dhule road, Tal. Chalisgaon, Dist. Jalgaon.

ABSTRACT :

This article review critically examines "Regulating Medicines in Europe: An In-Depth Analysis of the European Medicines Regulatory Network and Its Evolving Framework." The original article provides a comprehensive overview of the European Medicines Regulatory Network (EMRN), a collaborative framework that encompasses the European Medicines Agency (EMA), the Heads of Medicines Agencies (HMA), National Competent Authorities (NCAs), and the European Commission. It outlines how the EMRN governs the regulation of medicines in the EU through centralized and decentralized procedures and highlights key strategic developments for 2025–2028, including digitalization, real-world evidence integration (DARWIN EU), and improved access to medicines.

This review evaluates the strengths of the article, such as its clear structure, practical examples, and focus on innovation. It also discusses notable limitations, including a lack of empirical data, minimal stakeholder perspective, and limited critical analysis of challenges within the network. The review emphasizes the article's value as a resource for understanding European pharmaceutical regulation and its contribution to regulatory science. By situating the EMRN as a model for international cooperation and innovation, the article reinforces the EU's leadership in health governance and highlights opportunities for future research and policy development.

KEY WORDS : European Medicines Agency (EMA), Nation competent Authorities (NCAs), European Medicine Regulatory Network (EMRN), European Commission, Pharmaceutical Regulation, Marketing Authorization.

1. INTRODUCTION

The regulation of medicines plays a pivotal role in safeguarding public health, ensuring that patients have timely access to safe, effective, and high-quality therapeutic products. In the context of the European Union (EU), where multiple countries operate under a unified yet complex framework, the regulation of medicinal products demands a collaborative and dynamic system. The article, "Regulating Medicines in Europe: An In-Depth Analysis of the European Medicines Regulatory Network and Its Evolving Framework," provides a comprehensive overview of the European Medicines Regulatory Network (EMRN) and its structural, strategic, and scientific evolution. This review expands upon the key elements of the article, examining its contributions, evaluating its strengths and weaknesses, and reflecting on its significance within the wider scope of pharmaceutical regulatory science and healthcare policy.

The importance of efficient and harmonized regulation in the EU has grown significantly in recent decades. The pharmaceutical industry is global, yet regulation often remains a national competence. This dichotomy has made regional cooperation essential. The EMRN, as depicted in the article, is not merely a regulatory structure but a complex ecosystem that enables the European Union to maintain high standards of drug safety and innovation. This extended review aims to explore how the article captures this complexity and whether it adequately addresses the challenges, opportunities, and future directions of medicines regulation in Europe.

2.BACKGROUND

In recent years, the efficiency of the pharmaceutical regulatory system is under debate by governments as well as society. These concerns relate to the possibilities for innovation, lack of flexibility in the system, the timely availability on the market, pharmacovigilance and resources necessary to comply with and to check all requirements . An important issue for the pharmaceutical industry sector is that it is confronted with increasing research and development (R&D) costs, while at the same time the success rate of innovation seems to decline. In addition, recent developments, like the new European legislation for Pharmacovigilance, the development of the European Union (EU) Clinical Trial Regulation to replace Directive 2001/20/EC and the increased focus on the development of personalized medicine, provoke a re-assessment of the current system. The European Medicines Agency (EMA) itself emphasizes that "medicines regulation today is characterized by the increasing complexity of applications for new medicines, such as nanomedicines

or personalized medicines, and the drug-development environment as a whole." Finally, reduced public finances, the need for less (restrictive) rules and the call from society for greater transparency, require a review of the current regulatory system.

3.Aim Of The Study :

The aim of this study is to critically review and analyze the article "Regulating Medicines in Europe: An In-Depth Analysis of the European Medicines Regulatory Network and Its Evolving Framework," with a focus on understanding the structure, function, and strategic evolution of the European Medicines Regulatory Network (EMRN). This review seeks to evaluate the article's contributions to the field of pharmaceutical regulation, assess its strengths and limitations, and highlight the broader implications of the EMRN's regulatory practices for public health, innovation, and policy development within the European Union and beyond.

DEFINATION AND SCOPE

Definition : The European Medicines Regulatory Network (EMRN) is a cooperative framework that brings together the European Medicines Agency (EMA), the Heads of Medicines Agencies (HMA), National Competent Authorities (NCAs) of EU and EEA member states, and the European Commission. This network is responsible for the scientific evaluation, supervision, and safety monitoring of medicines developed and marketed within the European Union. It operates through both centralized and decentralized regulatory procedures to ensure that medicines available in the EU meet high standards of quality, safety, and efficacy.

SCOPE: This review focuses on evaluating the structure, operations, and strategic evolution of the EMRN as presented in the article. The scope includes: An overview of the EMRN's regulatory framework, including centralized and decentralized procedures Strategic priorities outlined in the EMA-HMA 2025–2028 vision Key regulatory innovations, such as DARWIN EU and electronic Product Information (ePI) Mechanisms of pharmacovigilance and quality control within the network A critical analysis of the article's clarity, comprehensiveness, and limitations An assessment of the EMRN's broader impact on EU public health policy and global regulatory science.

3.THE BIRTH OF A EUROPEAN FRAMEWORK 1965

The emergence of a European framework, 1965

The response to these events differed from nation to nation. Several years before the Thalidomide event, in 1958, the Netherlands established a Pharmaceutical law along with a regulatory body – het College ter beoordeling van Verpakte geneesmiddelen. However, even after the full implications of thalidomide were understood, it took several years—until 1963—before the law was enacted . Pre-market regulations for pharmaceuticals were established in France, the United Kingdom, and Germany in 1967, 1968, and 1976 respectively . At the European level, measures were implemented more quickly. In 1964, a Convention was established for the creation of a European Pharmacopoeia among eight member states of the Council of Europe: Belgium, France, Germany, Italy, Luxembourg, the Netherlands, Switzerland, and the United Kingdom. The European Economic Community and the World Health Organization (WHO) both gained observer status in the European Pharmacopoeia-Committee.

The convention relied on a dual commitment:

1. To establish a Common pharmacopoeia through both financial support and human resources;

2. To establish it as the official pharmacopoeia, if needed, substituting the current national Requirements.

The European Economic Community (EEC) responded to the thalidomide tragedy by reinforcing national drug regulations through Directive 65/65/EEC in 1965. It required all member states to implement pre-market authorization for medicines, based solely on safety, efficacy, and quality—not political or economic motives. Although the EEC's founding Treaty of Rome (1957) had no health provisions, it used trade-related clauses (e.g., free movement of goods and services) to justify harmonized pharmaceutical laws. This economic basis for regulating health products created ongoing tension between public health goals and market integration. While Directive 65/65 aimed to protect public health, it also stressed that regulation must not hinder the growth of the pharmaceutical industry, showing the EEC's delicate balance between health and economic priorities.

4.EUROPEAN MEDICINES REGULATORY SYSTEM:

The European Medicines Regulatory System is a unique and collaborative framework designed to ensure that all medicines available in the European Union (EU) are safe, effective, and of high quality. It brings together national and EU-level institutions to evaluate, authorize, and monitor medicines, ensuring consistent standards across all member states.

At the heart of this system is the European Medicines Regulatory Network (EMRN), a partnership involving the European Medicines Agency (EMA), the Heads of Medicines Agencies (HMA), National Competent Authorities (NCAs) of each EU/European Economic Area (EEA) member state, and the European Commission. Together, these bodies coordinate regulatory processes and share expertise and resources to avoid duplication and ensure efficiency.

FIGURE 1.EUROPEAN MEDICINE SYSTEM

5.Safety Monitoring of Medicines :

In Europe, the safety of all medicines is carefully checked throughout their entire time on the market. If patients or healthcare professionals notice any side effects, they must report them. These reports are stored in a database called EudraVigilance, which is managed by the European Medicines Agency (EMA). The EMA and EU Member States regularly check this data to spot any new safety concerns and make sure medicines remain safe for everyone to use.

1.Systems for Monitoring the Safety of Medicines Post-Authorization:

Pharmacovigilance System: The pharmacovigilance system encompasses a network of stakeholders, including pharmaceutical companies, regulatory authorities, healthcare professionals, and patients, collaborating to ensure the ongoing safety of medicines. Pharmaceutical companies (MAHs) are responsible for collecting and analyzing safety data from various sources, including spontaneous reports, clinical trials, scientific literature, and post-authorization studies.

Risk Management Plans (RMPs): Risk management plans (RMPs) are tailored risk minimization strategies developed for certain medicinal products with identified or potential risks. RMPs are dynamic documents that evolve throughout the lifecycle of the medicine, reflecting emerging safety data and regulatory requirements. Key components of RMPs include a description of the safety profile of the medicine, identification and characterization of risks, risk minimization measures, and plans for post-authorization safety studies.

2.Reporting Requirements for Adverse Drug Reactions:

Adverse Drug Reaction Reporting: Reporting of suspected adverse drug reactions (ADRs) is a cornerstone of pharmacovigilance, providing valuable safety data for the ongoing monitoring and assessment of medicinal products.

Electronic Reporting Systems: Electronic reporting systems, such as EudraVigilance, facilitate the efficient collection, analysis, and dissemination of pharmacovigilance data within the European Union (EU).

3.Signal Detection and Risk Management Strategies:

Signal Detection: Signal detection involves the systematic analysis of pharmacovigilance data to identify potential safety signals indicative of previously unknown adverse reactions or changes in the frequency or severity of known adverse reactions.

Key Regulatory Procedures

There are three main regulatory procedures for the approval of medicines in the EU:

Centralized Procedure: Managed by the EMA, this process allows a company to submit a single marketing authorization application for evaluation by the Committee for Medicinal Products for Human Use (CHMP). If approved, the product is authorized in all EU and EEA countries. This is mandatory for innovative medicines, such as those for cancer, HIV, and orphan diseases.

Decentralized Procedure (DCP): Used when a medicine has not yet been authorized in any EU country. The applicant requests simultaneous approval in multiple countries, designating one as the Reference Member State to lead the evaluation.

Mutual Recognition Procedure (MRP): Applied when a medicine has already been approved in one EU country, and the company wishes to extend that approval to other member states. The original evaluation is recognized by the additional countries.

1. Pharmacovigilance and Safety Monitoring

Post-marketing surveillance, known as pharmacovigilance, is a crucial part of the regulatory framework. The EudraVigilance system collects and analyzes data on adverse drug reactions (ADRs) across the EU. The Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA evaluates safety concerns and can recommend regulatory action, including withdrawal of a medicine.

2. Support for Innovation

The regulatory network also supports innovation and public health preparedness. The EMA offers scientific advice, guidance on clinical trials, and incentives for orphan drugs and pediatric medicines. One key initiative is DARWIN EU (Data Analysis and Real World Interrogation Network), which uses real-world evidence to support regulatory decisions.

3. Role of the European Commission

The European Commission adopts final decisions on the authorization of medicines under the centralized procedure. It ensures the legal implementation of regulatory decisions and coordinates legislation that affects the pharmaceutical sector across the EU.

4. Balancing Health and Market Integration

The EU regulatory system is built not only to safeguard public health but also to promote the internal market. Directive 65/65/EEC, introduced after the thalidomide disaster, was the first step toward harmonized pharmaceutical laws in the EU. It required that all medicines be authorized based on scientific criteria, not political or economic interests.

By working closely together, Member States reduce duplication, share the workload and ensure the efficient and effective regulation of medicines across the EU.

6. Marketing Authorisations :

To ensure that all medicines in the European Union (EU) are safe, effective, and of high quality, they must be approved before they can be sold or used. This process is known as marketing authorisation. One of the main ways to get this approval is through the centralised procedure, which is managed by the European Medicines Agency (EMA). In the centralised procedure, pharmaceutical companies submit a single application to the EMA. The application is scientifically reviewed by either the Committee for Medicinal Products for Human Use (CHMP) or the Committee for Veterinary Medicinal Products (CVMP). After completing the assessment, the committee gives a recommendation to the European Commission. If approved, the medicine receives a centralised marketing authorisation, which is automatically valid in all EU member states. This process helps avoid the need for separate national approvals in each country, saving time and ensuring consistency. The centralised procedure is mandatory for most innovative medicines, such as treatments for cancer, autoimmune diseases, and rare (orphan) diseases. This system supports faster access to important new therapies across the EU, while maintaining high safety and quality standards for patients.



FIGURE 2. MARKETING AUTHORISATION IN EUROPE

7.THE ROLE OF THE EUROPEAN COMMISSION :

The European Commission plays a central role in the functioning of the European Union (EU). It acts as the executive branch of the EU and is responsible for proposing legislation, implementing decisions, upholding the EU treaties, and managing the day-to-day business of the EU. Here is an overview of its main roles:

1. Proposing Legislation : The Commission is the only EU institution that can initiate legislation. It drafts proposals for new European laws, which are then submitted to the European Parliament and the Council of the European Union for approval. These proposals are usually based on consultations with stakeholders, member states, and experts.

2. Enforcing European Law : The Commission ensures that EU law is correctly applied in all member states.If a country fails to comply with EU law, the Commission can launch infringement proceedings and may refer the case to the European Court of Justice.

3. Implementing EU Policies and Budget: It manages and implements the EU's budget and policies, such as regional development, agriculture, research, and environmental protection. The Commission works with national and regional authorities to deliver EU-funded programs.

4. Representing the EU Internationally: The Commission represents the EU in international forums and trade negotiations (e.g., with the World Trade Organization).It speaks on behalf of the EU in areas where the EU has exclusive competence.

5. Upholding EU Values and Treaties: As "guardian of the treaties," the Commission ensures that all member states and EU institutions respect the principles and rules set out in the EU treaties.It promotes EU values like democracy, human rights, and the rule of law.

The European Commission can also take action Concerning other aspects of medicine regulation:

• Right of initiative – it can propose new or Amended legislation for the pharmaceutical Sector;

• Implementation – it can adopt implementing Measures as well as oversee the correct Application of EU law on pharmaceuticals;

• Global outreach – it ensures appropriate Collaboration with relevant international Partners and promotes the EU regulatory System globally.

8.ROLE OF EUROPEAN MEDICINE AGENCY:

The European Medicines Agency (EMA) is tasked with the scientific assessment of medicines, with a particular focus on innovative and high-tech drugs developed by pharmaceutical companies for use within the European Union. Established in 1995, the EMA was created to make the most effective use of scientific expertise across Europe in the evaluation, supervision, and monitoring of medicines' safety (pharmacovigilance). Experts contribute to the EMA's activities by serving on its scientific committees, working parties, scientific advisory groups, and other special advisory bodies, or by being part of national assessment teams that carry out evaluations of medicines.

Figure 3. EUROPEAN MEDICINE AGENCY

Ema's Scientific Committees

1. Committee for Medicinal Products for Human Use (CHMP)
2. Pharmacovigilance Risk Assessment Committee (PRAC)
3. Committee for Medicinal Products for Veterinary Use (CMVP)
4. Committee for Orphan Medicinal Products (COMP)
5. Committee on Herbal Medicinal Products (HMPC)
6. Committee for Advanced Therapies (CAT)
7. Paediatric Committee (PDCO)

9.EUROPEAN REGULATORY NETWORK :

The European Regulatory Network is a system that brings together different organizations to make sure all medicines used in the European Union (EU) are safe, effective, and high quality. This network includes:

The European Medicines Agency (EMA)

The European Commission

The national regulatory authorities from EU member countries, plus Iceland, Norway, and Liechtenstein These groups work closely to review, approve, and monitor medicines across Europe.

Main Parts of the Network:

1. European Medicines Agency (EMA): Organizes the scientific review of new medicines. Monitors the safety of medicines already on the market. Offers expert advice to help guide decisions.

2. European Commission: Gives the final approval for medicines through the centralized system. Writes and enforces EU laws on medicines.Makes sure all member countries follow the same rules.

3. National Competent Authorities (NCAs): These are the national agencies in each EU country. They help assess new medicines and perform inspections. They also manage medicine approvals at the national level.

10.EUROPEAN REGULATORY FRAMEWORK :

The regulatory framework is the set of rules and systems used to control how medicines are tested, approved, and monitored in Europe. It makes sure the process is the same in every country, and that people can trust the medicines they use.

Key Features: Centralized Procedure:A company can apply once to the EMA and, if approved, their medicine can be sold in all EU/EEA countries. Decentralized & Mutual

Recognition Procedures: Used for medicines that don’t go through EMA. Companies apply in several countries at once, and they recognize each other’s assessments.

Safety Monitoring (Pharmacovigilance): After a medicine is on the market, its safety is closely tracked. If problems are found, actions can be taken quickly.

Quality Standards:Rules like Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), and Good Distribution Practice (GDP) are followed to ensure high standards in how medicines are made, tested, and delivered.

Support for Innovation: The framework is updated often to include new types of treatments, like gene therapy or digital health tools.

FIGURE 4.FRAMEWORK RELIES ON FIVE CRITICAL ELEMENT

11.DISCUSSION :

The review of "Regulating Medicines in Europe: An In-Depth Analysis of the European Medicines Regulatory Network and Its Evolving Framework" reveals both the complexity and strengths of the European Union's regulatory architecture for medicinal products. The European Medicines Regulatory Network (EMRN) stands out as a robust collaborative mechanism, enabling harmonized decision-making across diverse national systems. This structure has proven effective in maintaining high standards for drug safety, quality, and efficacy across the EU.

One of the most significant strengths highlighted is the multi-tiered structure of the EMRN. The central role of the European Medicines Agency (EMA), in conjunction with the Heads of Medicines Agencies (HMA) and National Competent Authorities (NCAs), creates a well-integrated network capable of managing both routine and complex evaluations. Procedures such as the centralized, decentralized, and mutual recognition pathways offer flexible, yet standardized options for marketing authorization, catering to a wide range of medicinal products.

The article rightly underscores the Importance of post-marketing surveillance through pharmacovigilance systems such as EudraVigilance and the Pharmacovigilance Risk Assessment Committee (PRAC). These mechanisms exemplify the EU's commitment to continuous monitoring of drug safety, addressing emerging risks, and taking regulatory action when needed. However, while these systems are technically robust, there is limited discussion in the original article about how efficiently these measures are implemented across member states, especially regarding the variability in resources and expertise. Another forward-looking element in the regulatory framework is the integration of real-world evidence (RWE) via DARWIN EU, and the shift toward digital tools such as electronic product information (ePI). These innovations are in line with global trends toward personalized medicine and data-driven decision-making. Yet, the article does not fully explore the challenges of implementation, including data privacy, interoperability between national databases, or the readiness of healthcare systems to integrate such innovations.

12.CONCLUSION :

1.Critical Evaluation

While the original article is strong in clarity and structure, it lacks empirical evidence, stakeholder insights, and a deep critical analysis of system inefficiencies or political-economic tensions.

2. Public Health Impact

The EMRN serves as a model of regulatory cooperation, balancing innovation with public safety. Its initiatives—like DARWIN EU and ePI—show the EU's leadership in integrating digital technologies and real-world data into regulatory science.

3.Policy and Innovation Synergy

The dual aim of protecting public health and fostering a competitive pharmaceutical industry remains a complex yet necessary balance. The EMRN plays a pivotal role in harmonizing market access while upholding rigorous scientific evaluation.

4.Future Outlook

With strategic plans for 2025–2028 focusing on digitalization, personalized medicine, and real-world evidence, the EMRN is well-positioned to meet future challenges. However, transparency, stakeholder engagement, and adaptive legislation must remain priorities.

13. FUTURE SCOPE :

1.Enhanced Use of Real-World Evidence (RWE)

The integration of real-world data through initiatives like DARWIN EU is a promising frontier. In the future, RWE will play a more central role in regulatory decision-making, especially for post-marketing surveillance, rare diseases, and personalized medicine. This requires standardized data collection methods, interoperability across health systems, and regulatory guidance on RWE use.

2. Digital Transformation and Artificial Intelligence

As digital health technologies expand, the EMRN must develop new guidelines for evaluating digital therapeutics, AI-based diagnostics, and algorithm-driven decision tools. The network will need to address ethical considerations, data governance, and transparency in algorithmic decision-making to maintain public trust.

3. Personalized and Advanced Therapies

The growth of gene therapies, mRNA platforms, cell-based treatments, and nanomedicines demands adaptive regulatory models. Future frameworks must ensure that these innovative therapies are evaluated efficiently while maintaining safety and efficacy standards.

4. Global Regulatory Alignment

In an increasingly interconnected world, regulatory collaboration beyond the EU will be essential. The EMRN is well-positioned to play a leadership role in harmonizing standards with global agencies (e.g., FDA, WHO, ICH), facilitating mutual recognition, and coordinating during public health emergencies.

5. Strengthening Pharmacovigilance Systems

Future pharmacovigilance will increasingly rely on automated data analytics and real-time monitoring. Enhancing EudraVigilance, integrating AI, and improving public engagement in adverse event reporting are key areas of growth.

6.Improved Stakeholder Engagement The regulatory process must become more inclusive. Involving patients, clinicians, industry, and academia in the co-creation of regulatory policies will enhance transparency, public confidence, and the real-world applicability of decisions.

7. Sustainability and Resource Optimization

Given the growing workload and complexity of applications, optimizing the use of resources across national agencies will be critical. Greater work-sharing, digital tools, and performance monitoring will be necessary to maintain efficiency.

8. Regulatory Preparedness for Future Crises

COVID-19 exposed the importance of regulatory agility during health emergencies. Future frameworks should institutionalize emergency protocols, fast-track mechanisms, and inter-agency coordination to respond rapidly to emerging threats.

14. REFERENCE :

1) European Medicines Agency. (2022). About us. https://www.ema.europa.eu/en/about-us

2) European Commission. (2021). Pharmaceutical Strategy for Europe. https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe_en

3) European Medicines Agency. (2023). EMA Regulatory Science Strategy to 2025. https://www.ema.europa.eu/en/documents/report/ema-regulatory-science-strategy-2025_en.pdf

4) European Parliament and Council. (2004). Regulation (EC) No 726/2004. Official Journal of the European Union.

5) Directive 2001/83/EC of the European Parliament and of the Council. (2001). Community code relating to medicinal products for human use.

6) European Commission. (2020). Clinical Trials Regulation (EU) No 536/2014. https://euclinicaltrials.eu

7) European Medicines Agency. (2018). EudraVigilance – European database of suspected adverse drug reaction reports. https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance

8) Eichler, H. G., et al. (2011). Adaptive licensing: Taking the next step in the evolution of drug approval. Clinical Pharmacology & Therapeutics, 91(3), 426–437.

9) European Medicines Agency. (2023). DARWIN EU initiative. https://www.ema.europa.eu/en/darwin-eu

10) Council of the European Communities. (1965). Directive 65/65/EEC. OJ L 22, 9.2.1965, p. 369–373.

11) Heads of Medicines Agencies (HMA). (2021). About HMA. https://www.hma.eu/about-hma.html

12) EMA. (2021). Good Pharmacovigilance Practices (GVP). https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices

13) EMA. (2020). Digital transformation of regulatory processes. https://www.ema.europa.eu/en/about-us/how-we-work/digital-transformation

14) European Commission. (2019). Strengthening EU cooperation on health technology assessment (HTA). https://ec.europa.eu/health/technology_assessment/overview_en

15) EMA. (2022). Committee for Medicinal Products for Human Use (CHMP). https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp

16) EMA. (2022). Committee for Orphan Medicinal Products (COMP). https://www.ema.europa.eu/en/committees/committee-orphan-medicinal-products-comp

17) WHO. (2014). Pharmacovigilance: Ensuring the safe use of medicines. https://www.who.int/publications/i/item/9789241507943

18) EMA. (2022). Electronic product information (ePI) initiative. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/electronic-product-information

19) EMA. (2019). EMA and FDA collaboration. https://www.ema.europa.eu/en/about-us/international-cooperation/us-food-drug-administration-fda

20) Naci, H., Smalley, K. R., & Kesselheim, A. S. (2017). Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US FDA. JAMA, 318(7), 626–636.

21) European Medicines Agency. (2022). About us. https://www.ema.europa.eu/en/about-us

22) European Commission. (2021). Pharmaceutical Strategy for Europe. https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe_en

23) European Medicines Agency. (2023). EMA Regulatory Science Strategy to 2025. https://www.ema.europa.eu/en/documents/report/ema-regulatory-science-strategy-2025_en.pdf

24) European Parliament and Council. (2004). Regulation (EC) No 726/2004. Official Journal of the European Union.

25) Directive 2001/83/EC of the European Parliament and of the Council. (2001). Community code relating to medicinal products for human use.

26) European Commission. (2020). Clinical Trials Regulation (EU) No 536/2014. https://euclinicaltrials.eu

27) European Medicines Agency. (2018). EudraVigilance – European database of suspected adverse drug reaction reports. https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance

28) Eichler, H. G., et al. (2011). Adaptive licensing: Taking the next step in the evolution of drug approval. Clinical Pharmacology & Therapeutics, 91(3), 426–437.

29) European Medicines Agency. (2023). DARWIN EU initiative. https://www.ema.europa.eu/en/darwin-eu

30)Council of the European Communities. (1965). Directive 65/65/EEC. OJ L 22, 9.2.1965, p. 369–373.